Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In the literature: December 2018.
Gambardella V, Fleitas T, Cervantes A. Gambardella V, et al. Among authors: cervantes a. ESMO Open. 2018 Nov 28;3(7):e000468. doi: 10.1136/esmoopen-2018-000468. eCollection 2018. ESMO Open. 2018. PMID: 30559980 Free PMC article. No abstract available.
Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A. Tarazona N, et al. Among authors: cervantes a. Curr Oncol Rep. 2016 Jul;18(7):41. doi: 10.1007/s11912-016-0525-x. Curr Oncol Rep. 2016. PMID: 27215435 Review.
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A. Llorca-Cardeñosa MJ, et al. Among authors: cervantes a. Oncotarget. 2016 Sep 27;7(39):63424-63436. doi: 10.18632/oncotarget.11520. Oncotarget. 2016. PMID: 27566570 Free PMC article.
In the literature: October 2016.
Cervantes A. Cervantes A. ESMO Open. 2016 Oct 18;1(5):e000103. doi: 10.1136/esmoopen-2016-000103. eCollection 2016. ESMO Open. 2016. PMID: 27900207 Free PMC article. No abstract available.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Meulendijks D, et al. Among authors: cervantes a. Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9. Clin Cancer Res. 2017. PMID: 28600476 Clinical Trial.
604 results